Market Place
Sourcing Support
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
09 May 2024 //
BUSINESSWIRE
Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications
19 Apr 2024 //
ENDPTS
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
10 Apr 2024 //
BUSINESSWIRE
Alpine Immune Sciences to Participate in Upcoming Virtual Conference
20 Mar 2024 //
BUSINESSWIRE
Alpine Immune Provides Corporate Update and Full Year 2023 Financial Results
18 Mar 2024 //
BUSINESSWIRE
Alpine Immune to Report Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
BUSINESSWIRE
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
26 Feb 2024 //
BUSINESSWIRE
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
01 Feb 2024 //
BUSINESSWIRE
AbbVie agrees to end Alpine study early in return for fee cuts
21 Dec 2023 //
FIERCE BIOTECH
Alpine Immune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
18 Dec 2023 //
BUSINESSWIRE
Alpine Immune Up 8.60%: This Is What Analysts Are Now Forecasting
14 Dec 2023 //
STOCK REGISTER
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
20 Nov 2023 //
BUSINESSWIRE
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
BUSINESSWIRE
Alpine Immune Sciences Announces Proposed Public Offering
06 Nov 2023 //
BUSINESSWIRE
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
06 Nov 2023 //
BUSINESSWIRE
Alpine Immune Announces Appointment of Wolfgang Dummer as CMO
04 Oct 2023 //
BUSINESSWIRE
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
05 Sep 2023 //
BUSINESSWIRE
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy
30 Aug 2023 //
BUSINESSWIRE
Alpine Immune Sciences Announces Appointment of M. Christina Yi as CTO
22 Aug 2023 //
BUSINESSWIRE
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
BUSINESSWIRE
Alpine Immune Sciences to Present Data from RUBY-1
19 May 2023 //
BUSINESSWIRE
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Alpine Immune Sciences Announces Participation in the Bank of America Securities
01 May 2023 //
BUSINESSWIRE
Alpine Immune Reports Fourth Quarter and Full Year 2022 Financial Results
23 Mar 2023 //
BUSINESSWIRE
Alpine Immune Sciences to Present Povetacicept Phase 1 Study Data at Conferences
20 Mar 2023 //
BUSINESSWIRE
Alpine Immune to Report Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
BUSINESSWIRE
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
28 Feb 2023 //
BUSINESSWIRE
Alpine Immune to Participate in the SVB Securities Global Biopharma Conference
09 Feb 2023 //
BUSINESSWIRE
Alpine Immune Sciences Announces Participation in Fireside Chat
22 Nov 2022 //
BUSINESSWIRE
Alpine Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
07 Nov 2022 //
BUSINESSWIRE
Alpine Immune to Present ALPN-303 PhI Study Data at 2022 ASH Meeting
03 Nov 2022 //
BUSINESSWIRE
Alpine Immune Sciences Presents Update Of ALPN-303 Ph1 (RUBY-1) Clinical Data
03 Nov 2022 //
BUSINESSWIRE
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data
26 Oct 2022 //
BUSINESSWIRE
Alpine bails on phase 1 cancer asset after 2nd patient death
25 Oct 2022 //
FIERCEBIOTECH
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
20 Sep 2022 //
BUSINESSWIRE
Alpine to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs
12 Sep 2022 //
BUSINESSWIRE
Alpine Immune Sciences Announces Participation in September Investor Conferences
06 Sep 2022 //
BUSINESSWIRE
Alpine Announces R&D Day to Provide Clinical Updates on ALPN-303 & Davoceticept
30 Aug 2022 //
BUSINESSWIRE
Alpine Announces Inducement Grant to Andrew S. Sandler
18 Aug 2022 //
BUSINESSWIRE
Alpine Immune Sciences Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Evotec and Alpine Expand Partnership for Development of ALPN-303
10 Aug 2022 //
BUSINESSWIRE
Just - Evotec Biologics, Alpine Immune Sciences Expand Partnership for ALPN-303
09 Aug 2022 //
ACCESSWIRE
Alpine Immune Sciences to Participate in Fireside Chat at Wedbush Conference
04 Aug 2022 //
BUSINESSWIRE
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
19 Jul 2022 //
BUSINESSWIRE
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
07 Jun 2022 //
BUSINESSWIRE
Alpine Immune Sciences Announces Update on ALPN-303 at EULAR 2022
01 Jun 2022 //
BUSINESSWIRE
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO
26 May 2022 //
BUSINESSWIRE
Alpine Immune Announces FDA Removes Partial Clinical Hold on Davoceticept
24 May 2022 //
BUSINESSWIRE
Alpine Immune Sciences Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Davoceticept Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
12 Apr 2022 //
BUSINESSWIRE
Alpine Immune Sciences Announces Company Presentation and Update on AACR
05 Apr 2022 //
BUSINESSWIRE
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept
04 Apr 2022 //
BUSINESSWIRE
Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR
30 Mar 2022 //
BUSINESSWIRE
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
17 Mar 2022 //
PRESS RELEASE
Amneal Awarded Sub-License for Generic Version of Nirmatrelvir and Ritonavir
17 Mar 2022 //
BUSINESSWIRE
Alpine Immune Sciences Announces Oral Presentation at 2022 AACR
08 Mar 2022 //
BUSINESSWIRE
Alpine Cancer Drug Hit with Partial Hold after Patient Death
08 Mar 2022 //
BIOSPACE
Alpine Immune Sciences Announces Participation in March Investor Conferences
01 Mar 2022 //
PRESS RELEASE
Up to $1.5B on the Horizon for Alpine in four drug biobucks pact
17 Dec 2021 //
FIERCEBIOTECH
